Key factors associated with social distress after prostate cancer: Results from the United Kingdom Life after Prostate Cancer diagnosis study.


Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
06 2019
Historique:
received: 04 01 2019
revised: 16 04 2019
accepted: 19 04 2019
pubmed: 10 5 2019
medline: 28 2 2020
entrez: 10 5 2019
Statut: ppublish

Résumé

More men are living following a prostate cancer (PCa) diagnosis. They may need support to maximize the quality of their survival. Physical and psychological impacts of PCa are widely documented. Less is known about social impacts. We aimed to identify key factors associated with social distress following PCa. The Life After Prostate Cancer Diagnosis study is a UK national cross-sectional survey of men 18-42 months post diagnosis of PCa. Men (n = 58 930) were invited to participate by their diagnosing cancer centre including 82% of English NHS Trusts (n = 111) and 100% of all Health Boards in Northern Ireland (n = 5), Scotland (n = 14) and Wales (n = 6). Social distress was measured using the Social Difficulties Inventory (SDI-21), 16 item Social Distress scale with men assigned to 'socially distressed'/'not socially distressed' groups, according to published guidelines. Clinical and sociodemographic variables were collected from self-report and cancer registries. Response rate 60.8% (n = 35 823) of whom 97% (n = 29 351) completed the Social Distress scale (mean age = 71.2; SD = 7.88). The proportion of 'socially distressed' men was 9.4%. Multivariable logistic regression analysis revealed unemployment versus employment (odds ratio (OR): 11.58 [95% CI 9.16-14.63]) and ≥3 co-morbidities versus none (OR: 5.37 [95% CI 4.61-6.27]) as key associations. Others were Androgen Deprivation Therapy, External Beam Radiotherapy in combination with another treatment, age, prior mental health problems and living in a socio-economically deprived area. Most men following PCa are socially resilient. A simple checklist could help clinicians identify men at risk of social distress.

Sections du résumé

BACKGROUND
More men are living following a prostate cancer (PCa) diagnosis. They may need support to maximize the quality of their survival. Physical and psychological impacts of PCa are widely documented. Less is known about social impacts. We aimed to identify key factors associated with social distress following PCa.
METHODS
The Life After Prostate Cancer Diagnosis study is a UK national cross-sectional survey of men 18-42 months post diagnosis of PCa. Men (n = 58 930) were invited to participate by their diagnosing cancer centre including 82% of English NHS Trusts (n = 111) and 100% of all Health Boards in Northern Ireland (n = 5), Scotland (n = 14) and Wales (n = 6). Social distress was measured using the Social Difficulties Inventory (SDI-21), 16 item Social Distress scale with men assigned to 'socially distressed'/'not socially distressed' groups, according to published guidelines. Clinical and sociodemographic variables were collected from self-report and cancer registries.
RESULTS
Response rate 60.8% (n = 35 823) of whom 97% (n = 29 351) completed the Social Distress scale (mean age = 71.2; SD = 7.88). The proportion of 'socially distressed' men was 9.4%. Multivariable logistic regression analysis revealed unemployment versus employment (odds ratio (OR): 11.58 [95% CI 9.16-14.63]) and ≥3 co-morbidities versus none (OR: 5.37 [95% CI 4.61-6.27]) as key associations. Others were Androgen Deprivation Therapy, External Beam Radiotherapy in combination with another treatment, age, prior mental health problems and living in a socio-economically deprived area.
CONCLUSION
Most men following PCa are socially resilient. A simple checklist could help clinicians identify men at risk of social distress.

Identifiants

pubmed: 31071525
pii: S1877-7821(19)30031-1
doi: 10.1016/j.canep.2019.04.006
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

201-207

Informations de copyright

Copyright © 2019 University of Leeds. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Penny Wright (P)

Leeds Institute of Medical Research at St James's, University of Leeds, UK. Electronic address: e.p.wright@leeds.ac.uk.

Sarah Wilding (S)

Leeds Institute of Medical Research at St James's, University of Leeds, UK; Leeds Institute of Data Analytics, University of Leeds, UK.

Eila Watson (E)

Faculty of Health and Life Sciences, Oxford Brookes University, UK.

Amy Downing (A)

Leeds Institute of Medical Research at St James's, University of Leeds, UK; Leeds Institute of Data Analytics, University of Leeds, UK.

Peter Selby (P)

Leeds Institute of Medical Research at St James's, University of Leeds, UK.

Luke Hounsome (L)

National Cancer Registration and Analysis Service, Public Health England, UK.

Richard Wagland (R)

Faculty of Health Sciences, University of Southampton, UK.

David H Brewster (DH)

Deanery of Molecular, Genetic and Population Health Sciences, University of Edinburgh, UK.

Dyfed Huws (D)

Welsh Cancer Intelligence and Surveillance Unit, Public Health Wales, UK.

Hugh Butcher (H)

Leeds Institute of Medical Research at St James's, University of Leeds, UK.

Rebecca Mottram (R)

Leeds Institute of Medical Research at St James's, University of Leeds, UK; Leeds Institute of Data Analytics, University of Leeds, UK.

Therese Kearney (T)

Northern Ireland Cancer Registry, Queen's University Belfast, Royal Victoria Hospital, Belfast, UK.

Majorie Allen (M)

Leeds Teaching Hospitals NHS Trust, UK.

Anna Gavin (A)

Northern Ireland Cancer Registry, Queen's University Belfast, Royal Victoria Hospital, Belfast, UK.

Adam Glaser (A)

Leeds Institute of Medical Research at St James's, University of Leeds, UK; Leeds Institute of Data Analytics, University of Leeds, UK; Leeds Teaching Hospitals NHS Trust, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH